XML 48 R34.htm IDEA: XBRL DOCUMENT v3.22.2.2
SIGNIFICANT AGREEMENTS AND CONTRACTS - Narrative (Details) - USD ($)
 1 Months Ended 3 Months Ended 9 Months Ended
Jul. 26, 2022
Mar. 31, 2021
Sep. 03, 2019
Aug. 31, 2022
Mar. 31, 2022
Dec. 31, 2021
May 31, 2021
Sep. 30, 2019
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                        
Revenue from collaborative agreement                 $ 40,744,000 $ 7,076,000 $ 54,069,000 $ 42,347,000
Capitalized contract cost, amortization                     1,772,000 0
Mundipharma Medical Company                        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                        
Cost sharing percentage     50.00%                  
Mundipharma Medical Company | Affiliated Entity                        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                        
Collaborative agreement, maximum cost share     $ 31,200,000               32,200,000  
Collaborative agreement, potential transaction value     $ 568,400,000                  
Payments related to collaborative agreement                     30,000,000  
Accounts receivable, related parties                 500,000   500,000  
Mundipharma Medical Company | Affiliated Entity | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-10-01                        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                        
Revenue, remaining performance obligation, amount                 $ 18,000,000   $ 18,000,000  
Revenue, remaining performance obligation, expected timing of satisfaction, period                 2 years 3 months 18 days   2 years 3 months 18 days  
Mundipharma Medical Company | Affiliated Entity | License of Intellectual Property                        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                        
Revenue from collaborative agreement               $ 17,900,000        
Long-term portion of deferred revenue                 $ 11,100,000   $ 11,100,000  
Mundipharma Medical Company | Affiliated Entity | Milestone Achievement                        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                        
Revenue from collaborative agreement       $ 11,100,000   $ 2,800,000         13,900,000  
Mundipharma Medical Company | Affiliated Entity | Royalty                        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                        
Revenue from collaborative agreement                 0 0 0 0
Janssen Pharmaceuticals, Inc. | Affiliated Entity                        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                        
Collaborative agreement, maximum cost share                     61,200,000  
Payments related to collaborative agreement                     27,000,000  
Election to proceed notice, period post delivery of results   90 days                    
Termination provisions, required period of written notice   90 days                    
Accounts receivable, related parties                 4,500,000   4,500,000  
Janssen Pharmaceuticals, Inc. | Affiliated Entity | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-10-01                        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                        
Revenue, remaining performance obligation, amount                 $ 39,500,000   $ 39,500,000  
Revenue, remaining performance obligation, expected timing of satisfaction, period                 1 year 3 months 18 days   1 year 3 months 18 days  
Janssen Pharmaceuticals, Inc. | Affiliated Entity | License of Intellectual Property                        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                        
Revenue from collaborative agreement             $ 27,000,000          
Janssen Pharmaceuticals, Inc. | Affiliated Entity | Milestone Achievement                        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                        
Revenue from collaborative agreement         $ 3,000,000              
Janssen Pharmaceuticals, Inc. | Affiliated Entity | Royalty                        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                        
Revenue from collaborative agreement                 $ 0 $ 0 $ 0 $ 0
Janssen Pharmaceuticals, Inc. | Affiliated Entity | Upfront Payment                        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                        
Payments related to collaborative agreement   $ 27,000,000                    
Janssen Pharmaceuticals, Inc. | Affiliated Entity | R&D Funding                        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                        
Collaborative agreement, potential transaction value   58,200,000                    
Janssen Pharmaceuticals, Inc. | Affiliated Entity | Development, Regulatory, and Commercial Milestones                        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                        
Collaborative agreement, potential transaction value   $ 695,000,000                    
Melinta Therapeutics, Inc. | License of Intellectual Property                        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                        
Capitalized contract cost, gross                 2,000,000   2,000,000  
Capitalized contract cost, amortization                 1,800,000   1,800,000  
Capitalized contract cost, net                 200,000   200,000  
Melinta Therapeutics, Inc. | Affiliated Entity                        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                        
Collaborative agreement, potential transaction value $ 460,000,000                      
Payments related to collaborative agreement                     30,000,000  
Melinta Therapeutics, Inc. | Affiliated Entity | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-10-01                        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                        
Revenue, remaining performance obligation, amount                 $ 3,800,000   $ 3,800,000  
Revenue, remaining performance obligation, expected timing of satisfaction, period                 2 years 3 months 18 days   2 years 3 months 18 days  
Melinta Therapeutics, Inc. | Affiliated Entity | License of Intellectual Property                        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                        
Revenue from collaborative agreement       $ 25,900,000                
Melinta Therapeutics, Inc. | Affiliated Entity | Milestone Achievement                        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                        
Revenue from collaborative agreement                 $ 0   $ 0  
Melinta Therapeutics, Inc. | Affiliated Entity | Royalty                        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                        
Revenue from collaborative agreement                 $ 0   $ 0  
Melinta Therapeutics, Inc. | Affiliated Entity | Upfront Payment                        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                        
Payments related to collaborative agreement 30,000,000                      
Melinta Therapeutics, Inc. | Affiliated Entity | Development, Regulatory, and Commercial Milestones                        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                        
Collaborative agreement, potential transaction value $ 430,000,000